PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancer
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000022931
- Lead Sponsor
- Rakuwakai Otowa Hospital Breast oncology department
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of hypersensitivity reaction 2) Active double cander 3) Other severe complications, such as infections, diarrhea, uncontrolled angina, myocardial infarction within 6 months, heart failure. 4) Case of contraindication of this drug 5) Patients with peripheral nerve symptoms 6) Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 7) Judged ineligible based on physicians' decision
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pathological complete response rate
- Secondary Outcome Measures
Name Time Method Response rate, rate of breast conserving surgery, frequency and degree of adverse events, remains rate of peripheral neuropathy, QOL survey, Correlation of the QOL survey results and the pCR rate and the response rate